多发性骨髓瘤的临终关怀质量:加拿大安大略省基于人群队列的13年分析
该研究分析了加拿大安大略省2006至2018年间5095例多发性骨髓瘤患者的临终关怀质量,定义激进治疗为死亡前30天内两次以上急诊就诊、至少两次新住院或入住ICU,支持性治疗为死亡前两周内医生家访或死亡前30天内居家姑息护理或个人支持访问。结果显示23.2%的患者临终时接受化疗,55.6%在医院死亡,少数接受激进治疗(自体干细胞移植组28.3%,非移植组20.4%),多数接受支持性治疗(移植组65.4%,非移植组61.5%);支持性治疗在80岁以上及低收入社区患者中较少,从2006年的56.0%增至2018年的70.3%。尽管有改善,许多患者仍经历激进治疗,即使在公共资助医疗体系中也存在基于年龄、收入和社区规模的差异。
要点
- 5095例多发性骨髓瘤患者中,23.2%临终时接受化疗,55.6%在医院死亡。
- 激进治疗在自体干细胞移植组为28.3%,非移植组为20.4%。
- 支持性治疗在自体干细胞移植组为65.4%,非移植组为61.5%,从2006年56.0%增至2018年70.3%。
核心结论
- 尽管支持性治疗有所改善,许多多发性骨髓瘤患者临终时仍经历激进治疗,且在公共资助医疗体系中存在基于年龄、收入和社区规模的差异。
研究设计与样本
- 加拿大安大略省基于行政数据的队列分析,纳入2006年至2018年间5095例多发性骨髓瘤患者。
主要发现
- 23.2%的患者临终时接受化疗,55.6%的患者在医院死亡。
- 激进治疗在自体干细胞移植组为28.3%,非移植组为20.4%。
- 支持性治疗在自体干细胞移植组为65.4%,非移植组为61.5%。
- 支持性治疗从2006年的56.0%增加至2018年的70.3%。
- 80岁以上及低收入社区患者接受支持性治疗的可能性较低。
关键数值与推荐
- 激进治疗定义为死亡前30天内两次或以上急诊就诊,或死亡前30天内至少两次新住院,或死亡前30天内入住重症监护室。
- 支持性治疗定义为死亡前两周内医生家访,或死亡前30天内居家姑息护理或个人支持访问。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Optimizing end-of-life (EOL) care for multiple myeloma (MM) represents an unmet need. An administrative cohort in Ontario, Canada was analysed between 2006 and 2018. Aggressive care was defined as two or more emergency-department visits in the last 30 days before death, or at least two new hospitalizations within 30 days of death, or an intensive care unit (ICU) admission within the last 30 days of life. Supportive care was defined as a physician house-call in the last two weeks before death, or a palliative nursing or personal support visit at home in the last 30 days before death. Among 5095 patients, 23.2% of patients received chemotherapy at EOL and 55.6% of patients died as inpatient. A minority received aggressive care at EOL [28.3%: autologous stem cell transplant (ASCT), 20.4%: non-ASCT], and a majority received supportive care at EOL (65.4%: ASCT, 61.5%: non-ASCT). Supportive care was less likely to be received by those aged over 80 years and in lower-income neighbourhoods. Supportive care at EOL increased from 56.0% in 2006 to 70.3% in 2018. Despite improvements, many patients with MM experience aggressive care at EOL. Even in a publicly funded health care system, disparities based on age, income and community size are present.
引用
- Mohyuddin GR, Sinnarajah A, Gayowsky A, et al. Quality of end-of-life care in multiple myeloma: A 13-year analysis of a population-based cohort in Ontario, Canada. Br J Haematol. 2022. PMID: 35949180. doi:10.1111/bjh.18401
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。